State Street Corporation filed a Schedule 13G with the SEC on November 10, 2026, disclosing a beneficial ownership position in Acadia Pharmaceuticals Inc. as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: State Street Corporation reported beneficial ownership of 7,650,889 shares of Acadia Pharmaceuticals common stock.
  • Percent of class: The reported position represents 4.4% of the outstanding class of common stock.
  • Shared voting power: State Street disclosed shared voting power over 7,263,092 shares, with sole voting power of 0.
  • Shared dispositive power: The filing reports shared dispositive power over 7,650,889 shares, with sole dispositive power of 0.
  • Triggering date: The event requiring the filing occurred on September 30, 2026.
  • Subsidiaries involved: Five investment adviser subsidiaries are identified, including SSGA Funds Management, Inc. and State Street Global Advisors Europe Limited, among others.

State Street's Schedule 13G Filing for Acadia Pharmaceuticals Common Stock

State Street Corporation, a holding company organized in Massachusetts and headquartered at One Congress Street, Suite 1, Boston, MA 02114, submitted a Schedule 13G disclosing its beneficial ownership in Acadia Pharmaceuticals Inc. (NASDAQ:ACAD), whose principal executive offices are located at 12830 El Camino Real, Suite 400, San Diego, California, 92130. According to the filing, the event triggering the disclosure occurred on September 30, 2026, and the statement was signed by Alok Maheshwary, Senior Vice President, on November 9, 2026.

The filing reports that State Street beneficially owns 7,650,889 shares of Acadia Pharmaceuticals common stock (CUSIP 004225108), equating to 4.4% of the class. The company disclosed zero sole voting power and zero sole dispositive power. Shared voting power is reported as covering 7,263,092 shares, while shared dispositive power covers all 7,650,889 beneficially owned shares. The filing identifies State Street as a parent holding company or control person under Schedule 13G Item 3(g).

Five subsidiaries are listed as the entities that acquired the reported securities on behalf of State Street: SSGA Funds Management, Inc.; State Street Global Advisors Europe Limited; State Street Global Advisors Limited; State Street Global Advisors Trust Company; and State Street Global Advisors, Ltd., each classified as an investment adviser (IA). The filing certifies that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

What Was Disclosed

State Street Corporation disclosed a 4.4% beneficial ownership stake, totaling 7,650,889 shares of Acadia Pharmaceuticals common stock, as of September 30, 2026, held through five investment adviser subsidiaries with all voting and dispositive power exercised on a shared basis.